Vasodilatory Effect of the Stable Vasoactive Intestinal Peptide Analog RO 25-1553 in Murine and Rat Lungs

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Yin, Jun ^a,b,c,d   Wang, Liming ^a,b,c,d   Yin, Ning ^c,d   Tabuchi, Arata ^b   Kuppe, Hermann ^c   Wolff, Gerhard ^e   Kuebler, Wolfgang M ^b,c,d,f  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Hoffmann La Roche   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RO 25 1553; SILDENAFIL; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; EX VIVO STUDY; HEART OUTPUT; IN VIVO STUDY; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG CIRCULATION; LUNG FLUID; LUNG GAS EXCHANGE; LUNG HEMODYNAMICS; LUNG PERFUSION; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; LUNG VENTILATION; MALE; MOUSE; NONHUMAN; RAT; VASODILATATION;

ADMINISTRATION, INHALATION; ANIMALS; ANOXIA; HEMODYNAMICS; LUNG; MALE; MICE; PEPTIDES, CYCLIC; PULMONARY CIRCULATION; RATS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; VASOACTIVE INTESTINAL PEPTIDE; VASODILATOR AGENTS;

EID: 84884372878     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075861     Document Type: Article

References (78)

1. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, et al. (2007) Definition, epidemiology and natural history of COPD. Eur Respir J 30: 993-1013.
2. Said SI, Mutt V, (1970) Polypeptide with broad biological activity: isolation from small intestine. Science 169: 1217-1218.
3. Onoue S, Misaka S, Yamada S, (2008) Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn Schmiedebergs Arch Pharmacol 377: 579-590.
4. Dey RD, Shannon WA Jr, Said SI, (1981) Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell Tissue Res 220: 231-238.
5. Lundberg JM, Fahrenkrug J, Hokfelt T, Martling CR, Larsson O, et al. (1984) Co-existence of peptide HI (PHI) and VIP in nerves regulating blood flow and bronchial smooth muscle tone in various mammals including man. Peptides 5: 593-606.
6. Laburthe M, Couvineau A, Marie JC, (2002) VPAC receptors for VIP and PACAP. Receptors Channels 8: 137-153.
7. Usdin TB, Bonner TI, Mezey E, (1994) Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135: 2662-2680.
8. Busto R, Prieto JC, Bodega G, Zapatero J, Carrero I, (2000) Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides 21: 265-269.
9. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Simko B, et al. (1994) Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies. J Pharmacol Exp Ther 270: 1282-1288.
10. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Tocker JE, et al. (1994) Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis. J Pharmacol Exp Ther 270: 1289-1294.
11. Tannu SA, Renzetti LM, Tare N, Ventre JD, Lavelle D, et al. (2010) Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors. Br J Pharmacol 161: 1329-1342.
12. Said SI, (2006) Mediators and modulators of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 291: L547-L558.
13. Said SI, (2008) The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann N Y Acad Sci 1144: 148-153.
14. Minkes RK, McMahon TJ, Higuera TR, Murphy WA, Coy DH, et al. (1992) Analysis of systemic and pulmonary vascular responses to PACAP and VIP: role of adrenal catecholamines. Am J Physiol 263: H1659-H1669.
15. Cuttica MJ, Kalhan R, Shlobin OA, Ahmad S, Gladwin M, et al. (2010) Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 104: 1877-1882.
16. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, et al. (2005) Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127: 1531-1536.
17. Minai OA, Chaouat A, Adnot S, (2010) Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 137: 39S-51S.
18. Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, et al. (2013) Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 41: 1292-1301.
19. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, et al. (2010) Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 181: 270-278.
20. Blanco I, Santos S, Gea J, Guell R, Torres F, et al. (2013) Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J [Epub ahead of print].
21. Rietema H, Holverda S, Bogaard HJ, Marcus JT, Smit HJ, et al. (2008) Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 31: 759-764.
22. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, et al. (2008) A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 32: 619-628.
23. Urban N, Hill K, Wang L, Kuebler WM, Schaefer M, (2012) Novel pharmacological TRPC inhibitors block hypoxia-induced vasoconstriction. Cell Calcium 51: 194-206.
24. Spohr F, Busch CJ, Reich C, Motsch J, Gebhard MM, et al. (2007) 4-Aminopyridine restores impaired hypoxic pulmonary vasoconstriction in endotoxemic mice. Anesthesiology 107: 597-604.
25. Linehan JH, Haworth ST, Nelin LD, Krenz GS, Dawson CA, (1992) A simple distensible vessel model for interpreting pulmonary vascular pressure-flow curves. J Appl Physiol 73: 987-94.
26. Hentschel T, Yin N, Riad A, Habbazettl H, Weimann J, et al. (2007) Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology 106: 124-131.
27. Yin N, Kaestle S, Yin J, Hentschel T, Pries AR, et al. (2009) Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease. Crit Care Med 37: 980-986.
28. Tabuchi A, Mertens M, Kuppe H, Pries AR, Kuebler WM, (2008) Intravital microscopy of the murine pulmonary microcirculation. J Appl Physiol 104: 338-346.
29. Fenn WO, Rahn H, Otis AB, (1946) A theoretical study of the composition of the alveolar air at altitude. Am J Physiol 146: 637-653.
30. Peterson BT, Brooks JA, Zack AG, (1982) Use of microwave oven for determination of postmortem water volume of lungs. J Appl Physiol 52: 1661-1663.
31. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, et al. (2001) Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104: 424-428.
32. Ichinose F, Erana-Garcia J, Hromi J, Raveh Y, Jones R, et al. (2001) Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 29: 1000-1005.
33. Lovering AT, Romer LM, Haverkamp HC, Pegelow DF, Hokanson JS, et al. (2008) Intrapulmonary shunting and pulmonary gas exchange during normoxic and hypoxic exercise in healthy humans. J Appl Physiol 104: 1418-1425.
34. Whayne TF Jr, Severinghaus JW, (1968) Experimental hypoxic pulmonary edema in the rat. J Appl Physiol 25: 729-732.
35. Said SI, (1991) Vasoactive intestinal polypeptide (VIP) in asthma. Ann N Y Acad Sci 629: 305-318.
36. Onoue S, Yamada S, Yajima T, (2007) Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD. Peptides 28: 1640-1650.
37. Groneberg DA, Rabe KF, Fischer A, (2006) Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol 533: 182-194.
38. Ghatei MA, Sheppard MN, O'Shaughnessy DJ, Adrian TE, McGregor GP, et al. (1982) Regulatory peptides in the mammalian respiratory tract. Endocrinology 111: 1248-1254.
39. Paul S, Said SI, (1987) Characterization of receptors for vasoactive intestinal peptide solubilized from the lung. J Biol Chem 262: 158-162.
40. Morice A, Unwin RJ, Sever PS, (1983) Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet 2: 1225-1227.
41. Domschke S, Domschke W, Bloom SR, Mitznegg P, Mitchell SJ, et al. (1978) Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut 19: 1049-1053.
42. Hassan M, Refai E, Andersson M, Schnell PO, Jacobsson H, (1994) In vivo dynamical distribution of 131I-VIP in the rat studied by γ-camera. Nucl Med Biol 21: 865-872.
43. Bolin DR, Michalewsky J, Wasserman MA, O'Donnell M, (1995) Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 37: 57-66.
44. Dewit D, Gourlet P, Amraoui Z, Vertongen P, Willems F, et al. (1998) The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunol Lett 60: 57-60.
45. Kallstrom BL, Waldeck B, (2001) Bronchodilating properties of the VIP receptor agonist Ro 25-1553 compared to those of formoterol on the guinea-pig isolated trachea. Eur J Pharmacol 430: 335-340.
46. Linden A, Hansson L, Andersson A, Palmqvist M, Arvidsson P, et al. (2003) Bronchodilation by an inhaled VPAC2 receptor agonist in patients with stable asthma. Thorax 58: 217-221.
47. Szema AM, Hamidi SA, Lyubsky S, Dickman KG, Mathew S, et al. (2006) Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 291: L880-L886.
48. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, et al. (2007) Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115: 1260-1268.
49. Saga T, Said SI, (1984) Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians 97: 304-310.
50. Hamasaki Y, Saga T, Mojarad M, Said SI, (1983) Vasoactive intestinal peptide counteracts leukotriene D4-induced contractions of guinea pig trachea, lung, and pulmonary artery. Trans Assoc Am Physicians 96: 406-411.
51. Nandiwada PA, Kadowitz PJ, Said SI, Mojarad M, Hyman AL, (1985) Pulmonary vasodilator responses to vasoactive intestinal peptide in the cat. J Appl Physiol 58: 1723-1728.
52. Schmidt DT, Ruhlmann E, Waldeck B, Branscheid D, Luts A, et al. (2001) The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol 364: 314-320.
53. Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, et al. (2008) Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 32: 1289-1294.
54. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, et al. (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111: 1339-1346.
55. Galie N, Boonstra A, Ewert R, Gomez-Sanchez MA, Barbera JA, et al. (2010) Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 181: A2516 [Abstract].
56. Said SI, (2012) Vasoactive intestinal peptide in pulmonary arterial hypertension. Am J Respir Crit Care Med 185: 786.
57. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, et al. (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54: S43-S54.
58. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ, (2008) Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5: 549-55.
59. Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, et al. (2008) Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5: 543-8.
60. Chaouat A, Naeije R, Weitzenblum E, (2008) Pulmonary hypertension in COPD. Eur Respir J 32: 1371-1385.
61. Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, et al. (2009) Impact of pulmonary artery pressure on exercise function in severe COPD. Chest 136: 412-419.
62. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, et al. (1995) Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 107: 1193-1198.
63. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, et al. (2001) "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 164: 219-224.
64. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A, (1985) Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 131: 493-498.
65. Oswald-Mammosser M, Apprill M, Bachez P, Ehrhart M, Weitzenblum E, (1991) Pulmonary hemodynamics in chronic obstructive pulmonary disease of the emphysematous type. Respiration 58: 304-310.
66. Christensen CC, Ryg MS, Edvardsen A, Skjonsberg OH, (2004) Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients. Eur Respir J 24: 580-586.
67. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP, (1998) Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 113: 576-583.
68. Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF, (1972) Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 286: 912-918.
69. Bull T, Badesch DB, (2012) Sildenafil for COPD: a randomized crossover trial. COPD 9: 211-212.
70. Dreher M, Doncheva E, Schwoerer A, Walterspacher S, Sonntag F, et al. (2009) Preserving oxygenation during walking in severe chronic obstructive pulmonary disease: noninvasive ventilation versus oxygen therapy. Respiration 78: 154-160.
71. Yoshida M, Taguchi O, Gabazza EC, Kobayashi T, Yamakami T, et al. (1997) Combined inhalation of nitric oxide and oxygen in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 155: 526-529.
72. Marino WD, Granville P, (2006) The effect of iloprost inhalation on gas exchange in patients with COPD. Chest 130: 178S-179S [Abstract].
73. Dernaika TA, Beavin M, Kinasewitz GT, (2010) Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 79: 377-382.
74. Hegewald MJ, Elliott CG, (2009) Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. Chest 135: 536-537.
75. Boeck L, Tamm M, Grendelmeier P, Stolz D, (2012) Acute effects of aerosolized iloprost in COPD related pulmonary hypertension- a randomized controlled crossover trial. PLoS One 7: e52248.
76. Dehler M, Zessin E, Bartsch P, Mairbaurl H, (2006) Hypoxia causes permeability oedema in the constant-pressure perfused rat lung. Eur Respir J 27: 600-606.
77. Vivona ML, Matthay M, Chabaud MB, Friedlander G, Clerici C, (2001) Hypoxia reduces alveolar epithelial sodium and fluid transport in rats: reversal by β-adrenergic agonist treatment. Am J Respir Cell Mol Biol 25: 554-561.
78. Olschewski H, Olschewski A, Rose F, Schermuly R, Schutte H, et al. (2001) Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 138: 287-297.